http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105232565-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0038 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00 |
| filingDate | 2015-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105232565-B |
| titleOfInvention | The application of triterpene glucoside or its pharmaceutically acceptable salt in tumour radiotherapy sensitizer is prepared |
| abstract | The invention provides triterpene glucoside or a kind of new application of its pharmaceutically acceptable salt, tumour radiotherapy sensitizer can be prepared with it.It during using being applied to tumour radiotherapy as the tumour radiotherapy sensitizer that active component is prepared by triterpene glucoside and its pharmaceutically acceptable salt, can not only increase the radiosusceptibility of tumour, and the side effect of radiotherapy can also be reduced.Meanwhile triterpene glucoside is nontoxic, human normal cell will not be injured, therefore the present invention has potential applicability in clinical practice. |
| priorityDate | 2015-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.